VIP_oncohematology

Insights and updates on Multiple #Myeloma and CD30+ #Lymphoma.

[International Myeloma Foundation @IMFmyeloma]

Make sure that you read and subscribe to the #MyelomaMinute. Your source for the latest breaking news and information for #myeloma patients and caregivers. https://t.co/4V5feg49bN

[VIP_oncohematology @VIPOnHematology]

MC #lymphoma: R-CHOP/HD-ASCT associated with significantly lower hematological toxicity and economic burden | #lymsm https://t.co/mTPINaT0r8

[Lymphoma Hub @lymphomahub]

Results from 20-year retrospective study in MCL: R-CHOP/HD-ASCT strong choice as first-line therapy in physically fit adult MCL patients Read more here: https://t.co/dGD6FPoccr #lymsm #mcl #lymphoma

[Lymphoma Hub @lymphomahub]

Is interim PET scanning helpful for treatment planning in advanced stage Hodgkin lymphoma?
Read more here https://t.co/pPDg1huC88 #lymsm #lymphoma

[Raul Cordoba, MD, PhD @DrRaulCordoba]

Vitamin D deficiency and supplementation in patients with aggressive B-cell #lymphomas treated with immunochemotherapy #lymsm https://t.co/M0RrrFkUck

[VJHemOnc @VJHemOnc]

VIDEO: Curative strategy for smoldering #MultipleMyeloma: GEM-CESAR, with @mvmateos from University Hospital of Salamanca: https://t.co/k9mwmCfPOi @ASH_hematology #ASH2017 #MultipleMyeloma #MMSM #Myeloma #MM #SMM #MRD #MinimalResidualDisease #hemeonc

[VIP_oncohematology @VIPOnHematology]

Newly diagnosed multiple #myeloma: several studies confirmed an improvement in the response rate, progression-free survival, and overall survival (OS) with the administration of HDT/ASCT | #mmsm @JAMAOnc https://t.co/7ecAhWyO9l

[Multiple Myeloma Hub @MM_Hub]

'Review and meta-analysis of phase III RCTs assessing the role of HDT/ASCT in NDMM'. Read more: https://t.co/kB6DkKN7nR #mmsm #multiplemyeloma #haemtology @MM_Hub

[VIP_oncohematology @VIPOnHematology]

Baseline metabolic tumor volume is a strong prognostic factor in early stage Hodgkin #Lymphoma. It impacts the early response to treatment and improves risk stratification when combined with early PET | #lymsm
https://t.co/v9t3lAHRGs

[Multiple Myeloma Hub @MM_Hub]

Identification of a set of genes to stratify RRMM patients. Read here: https://t.co/KPognrzJ0y #mmsm #multiplemyeloma #haematology @MM_Hub

[LymphomaAction @LymphomaAction]

If you have been affected by primary or secondary central nervous system (CNS) lymphoma, you might be interested to know we have just updated our online information page #LymphomaAware #CNS #Lymphoma https://t.co/1QeaU97bkM

[VIP_oncohematology @VIPOnHematology]

In the contemporaneous era, therapies used for patients experiencing post allo-HCT #lymphoma relapse can extend survival | #lymsm https://t.co/ABKd4XHbQG

[Mehdi Hamadani, MD @MediHumdani]

Our large multicenter study shows that #Lymphoma patients can have durable remissions after a post alloHCT relapse. Case for NOT excluding them from clinical trials #bmtsm #lymsm @NEpperla @timfenske & Bachanova et al. https://t.co/3AHk88GWOl

[The ASCO Post @ASCOPost]

ASPIRE Trial: Final Overall Survival Results in Relapsed or Refractory Multiple Myeloma https://t.co/gM9Bjr9ZIi #MMSM #hematology

[VIP_oncohematology @VIPOnHematology]

Potential new drugs that block a safeguard used by cancer cells to stay alive in stressful conditions have shown promise against #myeloma | #mmsm https://t.co/Qk5fHw1GoX

[The ICR @ICR_London]

NEWS: Blocking cancer stress signal shows promise in bone marrow cancer #myeloma https://t.co/1KXVvCxf95

[VIP_oncohematology @VIPOnHematology]

Treating physicians should be aware of the increased risk of both subsequent malignant neoplasms and cardiovascular disease in patients treated for Hodgkin #Lymphoma until 2000 | #lymsm
https://t.co/sQ2Y9BnsOg

[ACS Journal Cancer @JournalCancer]

New! Trends in #MultipleMyeloma presentation, management, cost of care, & outcomes in the Medicare population: A comprehensive look at racial disparities https://t.co/E2I3cLYlcR @MayoClinic #MMSM

[VIP_oncohematology @VIPOnHematology]

Patients of minority race with #myeloma have had less increase in population-level survival in the early 21st century than white patients | #mmsm https://t.co/uRl6gg6Qzi

[Blood Advances @BloodAdvances]

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications #mmsm https://t.co/PC60QqJSnF

[WCM Lymphoma @WCMLymphoma]

Lymphoma Program Chief Dr. Peter Martin’s thoughts on the role of #transplant in people with relapsed follicular #lymphoma, via @OncLive Peer Exchange https://t.co/UBLTTuIn6I #lymsm

[VIP_oncohematology @VIPOnHematology]

Researchers were able to hold Hodgkin #lymphoma at bay in patients with relapsed disease for more than four years | #lymsm https://t.co/Cf9OogpWG4

[EMJ Hematology @EMJHematology]

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin #lymphoma https://t.co/phoGpx49M6

[UT MD Anderson @UTMDAnderson]

Insights on the diagnosis and staging of follicular #lymphoma from our expert @DrNathanFowler: https://t.co/ATaH4kyZ02 @OncLive #lymsm #endcancer

[VIP_oncohematology @VIPOnHematology]

Treatment with high-dose melphalan followed by #ASCT conferred longer PFS with minimal toxic effects compared with novel agents among patients with #MultipleMyeloma, according to results from a meta-analysis published in @JAMAOnc https://t.co/qxhl1VBj8Z

[HemOnc Today @HemOncToday]

#Stemcell transplant maintains benefit for multiple #myeloma in era of novel agents
https://t.co/cBB1sbxJWE

[ESH (Haematology) @ESHaematology]

Last Call for Clinical Cases! CLL and Indolent Lymphoma 2018 - https://t.co/IQjgpwC4rY